Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NHPwVWJHfW6ldHnvckBCe3OjeR?= NHnDfpkxNjYEoN88US=> MWCyOEBp NFfyVZp4[XSnch?= MVLtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> NGrlXlYzPTF{M{C4Ni=>
Eca109 M1nQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;IXmYxNjVxMj61M|Uh|ryP NVfVe3k5OjRxNEivO|IhcA>? NUHDcWJuf2G2ZYK= NF2wNI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NFThdJIzPTF{M{C4Ni=>
Eca109 MnrhSpVv[3Srb36gRZN{[Xl? M1K3XlAvPcLizszN NW\vdo5PPi9zMj:yOEBp NEXUeVl4[XSnch?= M1nzTolvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= Ml\BNlUyOjNyOEK=
Eca109 MmK2SpVv[3Srb36gRZN{[Xl? NWHqPXNIOC53wrFOwG0> M13Ie|I1KGh? M364TZdifGW{ MkfkbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NHW1boMzPTF{M{C4Ni=>
Eca109 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDXSW1JOC53wrFOwG0> NG[0O2MzPCCq Mlrae4F1\XJ? MoXObY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MoD5NlUyOjNyOEK=
Eca109 M1vBN2Z2dmO2aX;uJGF{e2G7 NELUeXExNjVxMTFOwG0> NXXQSHJvOjRiaB?= MXr3ZZRmeg>? Mor0[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? M2Dk[lI2OTJ|MEiy
SW1116  M1HYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DTd|AvPS9zL{KvOUDPxE1? NH7TXXU1QCCq M2PoNGROW09? MYDlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MknoNlQ5PzR{OE[=
LOVO MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XFSFAvPS9zL{KvOUDPxE1? MYi0PEBp NX;zWpJvTE2VTx?= Mn7V[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> M{D2T|I1QDd2Mki2
SW1116  NHPhXFJHfW6ldHnvckBCe3OjeR?= NEe0cG8yOCEQvF2= MYK0PEBp NG\uUVhFVVOR NXrXe3dtcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MWWyOFg4PDJ6Nh?=
LOVO NVWzeJYxTnWwY4Tpc44hSXO|YYm= NYDidJhQOTBizszN NUXRd2d5PDhiaB?= MVHEUXNQ M2DYNolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? M{nl[FI1QDd2Mki2
SW1116  MYDBdI9xfG:|aYOgRZN{[Xl? NVXJR5RTOTBizszN M3PwU|Q5KGh? MmHQSG1UVw>? MWPlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MlPVNlQ5PzR{OE[=
LOVO NFfWNo1CeG:ydH;zbZMhSXO|YYm= NHjaemEyOCEQvF2= MUG0PEBp MmHiSG1UVw>? NXfETYJY\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MorTNlQ5PzR{OE[=
RPMI-8226 NWrIZmk4SXCxcITvd4l{KEG|c3H5 NFHIRoEyNzJizszN Mn2zOFgwPzJxOU[gbC=> M4nvO2ROW09? NWrtPGtIcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFLs[m4zPDh|M{GwPC=>
OPM-2  NIfvPHVCeG:ydH;zbZMhSXO|YYm= MlHUNU8zKM7:TR?= M1ezUFczNzl4L{GyNEBp MV\EUXNQ NEe4UXpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYTl[Gh7OjR6M{OxNFg>
JJN3  MYLBdI9xfG:|aYOgRZN{[Xl? MUSwMlUwOSEQvF2= M3nuWFI1NzR6IHi= M1TsXGROW09? MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{e2W|I1QDN|MUC4
NCI-H929  M1jOSWFxd3C2b4Ppd{BCe3OjeR?= NGn0V|cyNzJizszN NF;HSIQ4Oi97Nj:xNlAhcA>? MWjEUXNQ NWLOfJNkcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4LvOlI1QDN|MUC4
RPMI-8226 NWDVZVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZfFU6OS9{IN88US=> MmLwNlQwPDhxN{KgbC=> NYOwNItSTE2VTx?= MnPmZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MlPWNlQ5OzNzMEi=
OPM-2  NUDvOnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLsVJVjOS9{IN88US=> MXiyOE81QC95MjDo MXrEUXNQ NEHGfZhi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MVSyOFg{OzFyOB?=
JJN3  NIW5bnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi1NE42NzFizszN M2rh[VI1NzR6L{eyJIg> MXjEUXNQ NYq5dVBn[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MlzpNlQ5OzNzMEi=
NCI-H929  NWXLWHNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxM|Ih|ryP MVSyOE81QC95MjDo MkPkSG1UVw>? NW\LWIVv[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NXW2V|RnOjR6M{OxNFg>
HeLa NX3IOm51U2mwYYPlJGF{e2G7 MYLLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx MnOyNlQ4QDByOUi=
HeLa M2\uXGtqdmG|ZTDBd5NigQ>? NISwdJBMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> MXeyOFc5ODB7OB?=
HeLa NIPFNHdMcW6jc3WgRZN{[Xl? MmLTT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NYfEU4ZzOjR5OECwPVg>
HeLa M3rSeGtqdmG|ZTDBd5NigQ>? MnfUT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> MluxNlQ4QDByOUi=
NB4 NX\MPWszTnWwY4Tpc44hSXO|YYm= NW\1UINYOi53L{WvO{42NzFyIN88US=> NYPsfXR3OjRiaB?= MmWySG1UVw>? NXjsO5N{cW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NWj2NFh3OjR2OES4O|A>
CD4+ CD25− T  MYjGeY5kfGmxbjDBd5NigQ>? MkK4NU82KM7:TR?= MYry[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> MWeyOFQ4PjN4MB?=
BV-173 NF64XYJCeG:ydH;zbZMhSXO|YYm= M{P1elAvOjVxMD61M|AvPzVxMTFOwG0> MYW0PE84Oi97NjDo M3jFNuKhWEKV NEPMUYVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NIHFbYUzPDR{M{[xNy=>
ML-1 Ml7NRZBweHSxc3nzJGF{e2G7 M2nPOVAvOjVxMD61M|AvPzVxMTFOwG0> MWC0PE84Oi97NjDo NV\IW4c3yqCSQmO= M1HLZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M{\oZVI1PDJ|NkGz
HL-60 MlW5RZBweHSxc3nzJGF{e2G7 MkWzNE4zPS9yLkWvNE44PS9zIN88US=> MV20PE84Oi97NjDo NXGzWFFRyqCSQmO= NHPlW2JqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NHrQWo0zPDR{M{[xNy=>
KG-1a NWnvcpg{SXCxcITvd4l{KEG|c3H5 MV[wMlI2NzBwNT:wMlc2NzFizszN Mlr1OFgwPzJxOU[gbC=> NUX2NnBzyqCSQmO= MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NUPlZpVDOjR2MkO2NVM>
BV-173 NWO4NGdQTnWwY4Tpc44hSXO|YYm= M1r1WVI2OC93MEDuUS=> M1TwUVQ5KGh? NF7yUZHDqFCEUx?= M1u0[olv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NEPicnYzPDR{M{[xNy=>
CEM M3TZRWZ2dmO2aX;uJGF{e2G7 M4Djc|I2OC93MEDuUS=> Mme5OFghcA>? M1;neuKhWEKV M2P1R4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NWG0U4x3OjR2MkO2NVM>
HL-60 NV\YeHU2TnWwY4Tpc44hSXO|YYm= MnTWNlUxNzVyMH7N NVvrb4puPDhiaB?= MoHuxsBRSlN? MXXpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M3HGRVI1PDJ|NkGz
ML-1 NV7v[2lVTnWwY4Tpc44hSXO|YYm= MmTqNlUxNzVyMH7N Mn;xOFghcA>? NH;lNYfDqFCEUx?= NUnZe2hOcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MV[yOFQzOzZzMx?=
DLD-1 MkTSSpVv[3Srb36gRZN{[Xl? NGn4fFMzPTBxNUCwcm0> M4LRXlQ5KGh? NXLFZWdlyqCSQmO= NV3FN4dE\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NELYWGMzPDR{M{[xNy=>
HCT-116 NXzteYlrTnWwY4Tpc44hSXO|YYm= NFn0b3czPTBxNUCwcm0> M{DldlQ5KGh? NGPnS|DDqFCEUx?= NGC5Z3ZldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M1Pn[VI1PDJ|NkGz
U937-A/E-9/14/18  NUnPe4hPSXCxcITvd4l{KEG|c3H5 MkHJNE4xOS9yLkGvNU8yOCEQvF2= MkHHOFghcA>? NHvV[JRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWW0VFRrOjR|MEC0OVY>
HT29 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp MkXNTWM2OD1zNECwxtEyPzlizszN MYqyOFE4OjB4MR?=
SW48 NFrY[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPPOVBrPzJiaB?= M1i3WWlEPTB;MUWuNuKyPi5{IN88US=> NX3Y[phMOjRzN{KwOlE>
HCT116 M3HMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF34[Fg4OiCq MVrJR|UxRTFwN9MxNE41KM7:TR?= MkezNlQyPzJyNkG=
HepG2 MWPGeY5kfGmxbjDBd5NigQ>? NEf4TpUxNjVxMTFOwG0> M1\Je|I1KGh? M1\1b2ROW09? MXv1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? NXvKPWNbOjRzNE[4O|Q>
LS174T NILK[ZdHfW6ldHnvckBCe3OjeR?= MnjLNE42NzFizszN NUH0dXhsOjRiaB?= MWrEUXNQ MnLvcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= M{\QeVI1OTR4OEe0
HepG2 M1roV2Fxd3C2b4Ppd{BCe3OjeR?= M2DVUVEwOTBxMUCwJO69VQ>? MoG2O{Bl NUizd5RMTE2VTx?= M1GyUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUWyOFE1Pjh5NB?=
LS174T NH3scGVCeG:ydH;zbZMhSXO|YYm= NUOwUm5tOS9zMD:xNFAh|ryP NFGweGk4KGR? NWi2UFdJTE2VTx?= MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn;aNlQyPDZ6N{S=
QBC-939 M4PSUmFxd3C2b4Ppd{BCe3OjeR?= MnzwNU8yOC9zMECg{txO MWm3JIQ> NFnxNHRFVVOR MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmLnNlQyPDZ6N{S=
U251 Mo\lRZBweHSxc3nzJGF{e2G7 MojBNU8yOC9zMECg{txO MYW3JIQ> M1PGS2ROW09? Ml[0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MojqNlQyPDZ6N{S=
HL-60 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG5Vo1{OSEQvF2= MXq0PEBp NY\seHlncW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= MUmyOFAxODN{NB?=
MDA‑MB‑453 MX3GeY5kfGmxbjDBd5NigQ>? NV7UTmxROC5{L{Gg{txO NEXYWIM4OiCq MmLHZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NWHVZm1nOjN6NESyNlg>
HCC1569 MYPGeY5kfGmxbjDBd5NigQ>? MmjyNE4zNzFizszN MofqO|IhcA>? NF7ZWGZk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NV3DVohrOjN6NESyNlg>
BT‑474 MWLGeY5kfGmxbjDBd5NigQ>? NE\3XlYxNjJxMTFOwG0> MYq3NkBp NFLzeYRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NUeweGJ2OjN6NESyNlg>
AGS M4fkSGFxd3C2b4Ppd{BCe3OjeR?= MWW1M|ExNzJyL{WwJO69VQ>? MoX1OFjDqGkEoB?= NFm4NXVFVVOR MnvEbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MWiyN|U5Ojd6NB?=
A549 MVHBdI9xfG:|aYOgRZN{[Xl? NX7F[oJOPS9zMD:yNE82OCEQvF2= MUe0POKhcMLi NHf1cHRFVVOR MVfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NUTHO|dlOjN3OEK3PFQ>
AGS  Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDROU8yOC9{MD:1NEDPxE1? NUXZZ2FTPDkEoHlCpC=> MlXXSG1UVw>? MmC4bY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg NGHHNoszOzV6Mke4OC=>
Kasumi-1 NEDWOVRCeG:ydH;zbZMhSXO|YYm= MWSwMlUh|ryP MXm0POKhcMLi M13GZYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NFPUNGwzOzR7M{O0PC=>
OCI-AML3 M4PwTGFxd3C2b4Ppd{BCe3OjeR?= M2HqZ|IvPSEQvF2= M2LQfVQ5yqCqwrC= NHfCSHdl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NYTMU2p5OjN2OUOzOFg>
MV4-11 MWrBdI9xfG:|aYOgRZN{[Xl? NYXN[3JEOi53IN88US=> MojGOFjDqGkEoB?= NHnzdJJl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NUD3SpFIOjN2OUOzOFg>
NK  MVvDfZRwfG:6aYT5JGF{e2G7 Mor1NE4xOi1{MDFOwG0> MlrWOUBl MnP3[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NIG0epUzOzN{OEC4PC=>
NK  M3LUTWFxd3C2b4Ppd{BCe3OjeR?= NXvpdnd2OC5yMj2yNEDPxE1? NFT1RoY2KGR? NH;4UXVl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? MlvzNlM{OjhyOEi=
NK  NIrQN2VHfW6ldHnvckBCe3OjeR?= MUSwMlAyNTJyIN88US=> MUS1JIQ> M1f3RoNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MmfwNlM{OjhyOEi=
MOLT4/DNR NWLnXmpRTnWwY4Tpc44hSXO|YYm= NWO5fWM2PSEQvF2= NV7wO5ZiPCCm MoHTdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> Mnz1NlMxPjB3N{C=
Jurkat/DOX MkDRSpVv[3Srb36gRZN{[Xl? MnXpOUDPxE1? NEf1dGM1KGR? NWnDeoJPemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? NHvEWZkzOzB4MEW3NC=>
MOLT4/DNR NGn0ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3OUDPxE1? M{LHSVQh\A>? NV;2ZoFbemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MWiyN|A3ODV5MB?=
Jurkat/DOX M17abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnZOUDPxE1? NGPybpc1KGR? M3:we5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= M13jOlI{ODZyNUew
ccRCC  NE\tSmFCeG:ydH;zbZMhSXO|YYm= NYfiS5QzOC5yMT2xNO69VQ>? MljxO|IhcA>? NET1eYxFVVOR M4HJd4hieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NXrJdmJyOjJ6Mk[0Olc>
TNBC  NUfHUZhjSXCxcITvd4l{KEG|c3H5 MUGwMlAyNTFyzszN MoD2O|IhcA>? M1SzeGROW09? MXjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MmHYNlI5OjZ2Nke=
A498 NFXKXXFCeG:ydH;zbZMhSXO|YYm= M4SyUlAvODFvMUFOwG0> NWH3TVVxPzJiaB?= NI\5UFFFVVOR MVrpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M3nnTFIzQDJ4NE[3
KIJ265T NWLzVmE4SXCxcITvd4l{KEG|c3H5 MXuwMlAyNTFyzszN NGrkVY44OiCq NH[5[JNFVVOR NFTmdnBqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M4PPT|IzQDJ4NE[3
MDA-231 NFL3eYtCeG:ydH;zbZMhSXO|YYm= MnX2NE4xOS1zMN88US=> MoO0O|IhcA>? NHOyTpVFVVOR Ml\UbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NYXYeFlqOjJ6Mk[0Olc>
BT-20 NXL0dFdjSXCxcITvd4l{KEG|c3H5 MWSwMlAyNTFyzszN MlTCO|IhcA>? M2LYNWROW09? NInrWZFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MmPRNlI5OjZ2Nke=
U937 NX[wbHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LiZ|UuOjBizszN MlTvNlQwPDhxN{KgbC=> NWC0S5NscW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NVmxWJNYOjJ5NkewNlE>
HL60 NGro[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW1MVIxKM7:TR?= M3j6SVI1NzR6L{eyJIg> M1X4bIlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NXnMOHVzOjJ5NkewNlE>
U937 MoXmRZBweHSxc3nzJGF{e2G7 M1TiWFE2KM7:TR?= M{PrW|I1NzR6L{eyJIg> NHGwU4RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWGyNlc3PzB{MR?=
HL60 NWP4N|lvSXCxcITvd4l{KEG|c3H5 MkPwNVUh|ryP NHe5OoEzPC92OD:3NkBp MW\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHjKe4czOjd4N{CyNS=>
LS411N  Mo\JRZBweHSxc3nzJGF{e2G7 M37heVAvPSEQvF2= NXntOW11PzJiaB?= NWnKRZd3cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs NE\mcogzOjR4MU[5OS=>
MDA-MB-231 NYLj[4pxSXCxcITvd4l{KEG|c3H5 M3rRUVExKM7:TR?= M3HnblQ5KGh? MnzEdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXHhdFlqOjF6OEe2PVc>
MCF-7  M3v2dGFxd3C2b4Ppd{BCe3OjeR?= MUexNEDPxE1? NF;hVmo1QCCq MlnQdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFLVfmczOTh6N{[5Oy=>
A375 NHfqcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jh[lAvPSEQvF2= M2HTT|EwPS96IHS= MlPobY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NETPbnQzOTd7Nk[yNi=>
SKMEL1 NUXk[GtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPGT3JwOC53IN88US=> NY\XfVl[OS93L{ig[C=> M1Li[IlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MknmNlE4QTZ4MkK=
SKMEL3 NI\yToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[4Wo4xNjVizszN NX;peI1TOS93L{ig[C=> NGLWe4xqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MonDNlE4QTZ4MkK=
SKMEL28 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17FZVAvPSEQvF2= M{DHOFEwPS96IHS= M1ricYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M2q1XlIyPzl4NkKy
MeWo MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz2Xo52OC53IN88US=> NFzNfFAyNzVxODDk NUPtNol7cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmnqNlE4QTZ4MkK=
B16 NYP0OJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDNdmkxNjVizszN NVv5NYt5OS93L{ig[C=> MX7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NUe3R3ZOOjF5OU[2NlI>
Ly 1 NYXPOG54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fvb|I1KGh? M37EfGlEPTB;Nz6zJO69VQ>? NXTnRZlDOjF5N{KwOFk>
Ly 7 M4\yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjWVmozPCCq M4TJOmlEPTB;MUCuO{DPxE1? NIKweVgzOTd5MkC0PS=>
Su-DHL6 M4f4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6VVQ{OjRiaB?= MkXrTWM2OO,:nkKwJO69VQ>? MnzQNlE4PzJyNEm=
Ly 10 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;DbYhCOjRiaB?= NY\MR5M4UUN3MP-8olIxKM7:TR?= M321RlIyPzd{MES5
RIVA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWeyOEBp MWPJR|Ux97zgMkCg{txO NX\jOXRMOjF5N{KwOFk>
Su-DHL2 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULa[Gt1OjRiaB?= NH\hVJdKSzVy78{eNlAh|ryP NVrFUnRMOjF5N{KwOFk>
Ly 1 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;iZXo1PDhiaB?= M3rRbGlEPTB;MD6zOEDPxE1? MlrmNlE4PzJyNEm=
Ly 7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKcZptPDhiaB?= M4e1SGlEPTB;MD6wNlUh|ryP MYCyNVc4OjB2OR?=
Su-DHL6 M3rQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnyR4RlPDhiaB?= NETSXI9KSzVy78{eNlAh|ryP NEnSWm8zOTd5MkC0PS=>
Ly 10 M1zBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IOlQ5KGh? NGGyPWxKSzVyPUGuPEDPxE1? NXHZSpppOjF5N{KwOFk>
RIVA M1\ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MneyOFghcA>? MYPJR|Ux97zgMkCg{txO NVHGdVJSOjF5N{KwOFk>
Su-DHL2 NXrGfVc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDRVQ5KGh? NIn6OlFKSzVyPUG3MlQh|ryP M13Ld|IyPzd{MES5
Ly 1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzrc|Y4OiCq MlzXTWM2OD1yLkCxJO69VQ>? M33vfFIyPzd{MES5
Ly 7 M1m4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjjcnd2PzJiaB?= MnH0TWM2OD1yLkCxPEDPxE1? M2rGRlIyPzd{MES5
Su-DHL6 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:3NkBp MmjZTWM2OD1zLk[g{txO MUOyNVc4OjB2OR?=
Ly 10 NEi2UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzuTYg4OiCq NVHvcY43UUN3ME2xMlIh|ryP NGLuPIMzOTd5MkC0PS=>
RIVA NFHHSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHmO|IhcA>? MV;JR|Ux97zgMkCg{txO M2jWWFIyPzd{MES5
Su-DHL2 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrNO|IhcA>? MUPJR|UxRTFzLkKg{txO Ml7lNlE4PzJyNEm=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03017131 Recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT03021395 Recruiting AML Institute of Hematology & Blood Diseases Hospital February 8 2017 Phase 1|Phase 2
NCT03226418 Recruiting Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia University of Nebraska|National Cancer Institute (NCI) July 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02203773 Active not recruiting Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML AbbVie|Genentech Inc. July 7 2015 Phase 1|Phase 2
NCT03066648 Recruiting Leukemia|Leukemia Myeloid|Leukemia Myeloid Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases Novartis Pharmaceuticals|Novartis July 6 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID